Technical validation of a new microfluidic device for enrichment of CTCs from large volumes of blood by using buffy coats to mimic diagnostic leukapheresis products

• Published in: Scientific reports 2020-11, Vol.10 (1), p.20312-20312, Article 20312
• Main Authors: Guglielmi, R., Lai, Z., Raba, K., van Dalum, G., Wu, J., Behrens, B., Bhagat, A. A. S., Knoefel, W. T., Neves, R. P. L., Stoecklein, N. H.
• Format: Article
• Language: English
• Subjects: 631/57; 631/67; 692/4028; 692/53; Biopsy; Blood & organ donations; Blood Buffy Coat - cytology; Blood products; Buffy coat; Cancer; Cell culture; Cell Line, Tumor; Experiments; Humanities and Social Sciences; Humans; Lab-On-A-Chip Devices; Leukapheresis; Leukapheresis - instrumentation; Leukocytes; Liquid Biopsy - instrumentation; Liquid Biopsy - methods; Load distribution; Metastasis; Microfluidics; Mimicry; multidisciplinary; Neoplasms - blood; Neoplasms - diagnosis; Neoplastic Cells, Circulating; Peripheral blood; Prostate; Science; Science (multidisciplinary); Tumor cell lines; Tumor cells
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-77227-3

Diagnostic leukapheresis (DLA) enables to sample larger blood volumes and increases the detection of circulating tumor cells (CTC) significantly. Nevertheless, the high excess of white blood cells (WBC) of DLA products remains a major challenge for further downstream CTC enrichment and detection. To address this problem, we tested the performance of two label-free CTC technologies for processing DLA products. For the testing purposes, we established ficollized buffy coats (BC) with a WBC composition similar to patient-derived DLA products. The mimicking-DLA samples (with up to 400 × 10 6 WBCs) were spiked with three different tumor cell lines and processed with two versions of a spiral microfluidic chip for label-free CTC enrichment: the commercially available ClearCell FR1 biochip and a customized DLA biochip based on a similar enrichment principle, but designed for higher throughput of cells. While the samples processed with FR1 chip displayed with increasing cell load significantly higher WBC backgrounds and decreasing cell recovery, the recovery rates of the customized DLA chip were stable, even if challenged with up to 400 × 10 6 WBCs (corresponding to around 120 mL peripheral blood or 10% of a DLA product). These results indicate that the further up-scalable DLA biochip has potential to process complete DLA products from 2.5 L of peripheral blood in an affordable way to enable high-volume CTC-based liquid biopsies.